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1. Introduction 
The field of neurological disorders becomes now one of the most important investigation 
areas in clinical medicine, whatever the toxicological, genetic, degenerative or 
environmental aetiology they have. Because it involves the main complex organ as target 
tissue, because also of the intrinsic specificity of the biological network of the nervous 
system, or the technical difficulty to access such a composite organ, the nervous diseases 
remain particularly difficult to study. Certainly, the rapid development of transgenic animal 
models of neurological diseases and the expanding growth of imaging techniques to 
functionally and non-invasively access some specific brain regions constitute a favourable 
situation to study the basis and the progression of some nervous diseases. However, the use 
of such transgenic animals or spontaneous animal models needs that the clinical symptoms 
are reproducible and that a prior knowledge of the aetiopathology of these diseases may 
exist. These latter conditions are not always available, especially concerning toxicology. In 
this case, how can both pathophysiology and therapies be investigated? Indeed, classically, 
when considering a toxicological approach, clinical signs, similar to those ascribed on the 
target species, need to be reproduced on the animal model. But how to do with disease 
displaying no known aetiology or with an animal model, on which it is impossible to 
reproduce, at least partially, some clinical signs of the target species? Furthermore, because 
of evident ethical reasons added to practical ones, some neurological disorders in humans or 
in large animals remain scarcely explored. “Omics” approaches seem to be a good 
alternative in the clinical medical research, enabling to take advantage of the global living 
system and, simultaneously of the control of the toxicological factor. To illustrate such an 
original approach, a neurological horse disease, Australian stringhalt, which has been 
described for several centuries, but for which aetiology is still only partially known, was 
reassessed using metabonomics in combination with other classical techniques. This has led 
to show how powerful this method may stand for in clinical medical research and, 
particularly in neurological studies. 
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2. Current neurological investigations: Advantages and limits of routinely 
used approaches and techniques 
2.1 Limits of classical studies 
Up to now, the neurological investigations tended to reproduce a human disease using a 
convenient animal model. However, they laboured to give results. In fact, it may appear 
surprising to recreate all the metabolic complexity prevailing in the genesis of a given 
disease and, to work on it, before having any knowledge of the specifically involved 
metabolic pathways specifically involved. Before considering an animal model as a 
convenient model of a human disease, it seems more consistent to record and describe all 
the putative impacts of a controlled stimulus on a living system without any a priori 
hypothesis because of our ignorance of the inherent metabolic disruptions involved. Indeed, 
this may help to efficiently tackle a neurological disease. 
2.2 Behavioural approaches 
The use of animal models of human diseases, on which some behavioural tests are carried 
out, is fundamental to investigate nervous disorders. The field of psychopharmacology or 
behavioural pharmacology enables to test and to measure effects of drugs on behaviour. The 
toxicological studies test the short- or long-term exposure, the acute intoxication or the 
chronic effects following administration of subclinical doses and the associated effects of 
chemical compounds or contaminants. Each behavioural manifestation in animal model 
tends to reflect a specific human behavioural alteration or cognitive effect like depression, 
anxiety, fear or schizophrenia. This may be susceptible to reveal a disruption in some mean 
way of neurological transduction involving, for example, dopamine, acetylcholine, 
amphetamine or catecholamine’s impairments. However, this approach has some limits. In 
case of the lack of any behavioural manifestation in animals, the conclusion isn’t that there is 
a lack of effect but only that there is an impossibility to give an interpretation of this lack of 
effect because of an inadequate “observation window” as in delayed toxicity of some 
contaminants for example. Moreover, the putative link between a visible behavioural 
impairment and a putative mechanistic explanation requires going back to the cerebral 
metabolism to translate the observed behavioural variance and to confirm the pertinence of 
metabolic pathways specifically involved. Most of the time, such behavioural approaches 
are hardly self-sufficient; they need to be completed by other studies such as metabolic, 
histological, anatomical or immunologic ones. 
2.3 Imaging techniques 
A wide range of imaging techniques provides powerful tools for studying tumours (Cooper 
et al., 2011), congenital diseases (Toga et al., 2006), metabolic and infectious diseases 
(Kastrup et al., 2005), development of organisms (Davis et al., 2011) and for realizing 
preclinical or clinical studies, or for measuring a treatment effect (Song et al., 2011). These 
techniques can also be used in neurotoxicology (Pogge and Slikker, 2004) or for exploring 
neurodegenerative or psychiatric disorders (Masdeu, 2011; Stoessl, 2011). The choice of one 
of these techniques is made according to some awaited answers to a specific anatomical, 
metabolic or functional information question, some of imaging techniques being able to 
perform several specific assessments. They are well adapted to describe functions in the 
frame of non-invasive in vivo studies, some being planned with a longitudinal follow-up. 
Concerning some specific tissues analyses, some compromises have to be done between the 
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spatial or the temporal resolution according to what it has to be focussed on. Among these 
different techniques, anatomic or functional imaging techniques have to be distinguished. 
The first ones, tomodensitometry and magnetic resonance imaging or MRI (Griffith et al., 
2007) provide highly detailed anatomic information. Their ability to give an access to in vivo 
biological information acquired non-invasively or to define a seemingly normal body 
composition and its perturbation in response to a pharmacological or a pathological event 
may facilitate exploration of nervous diseases (Frisoni and Filippi, 2005; Griffith et al., 2007; 
Tartaglia and Arnold, 2006). In parallel with the description of novel biomarkers coming 
from transgenic animal models developed for studying neurodegenerative diseases and 
more efficient therapies, the use of MRI and magnetic resonance spectroscopy (MRS) 
provide new information for in vivo neurochemistry, such as neuronal apoptosis, 
osmoregulation, energy metabolism, membrane function or signalling disruptions (Choi et 
al., 2007; Ross and Sachdev, 2004; Ross and Bluml, 2001). Most of clinical researches are 
based on the metabolites that are detectable using proton spectroscopy (Figure 1), which can 




























































































































































Fig. 1. 600.13 MHz 1H NMR spectra from aqueous extracts of brain in mouse (control 
animal) (from Domange, 2008) 
Nuclear magnetic resonance (or NMR) methods (MRI or MRS) can be successfully used to 
reveal neurological markers like N-acetyl-aspartate (a neuronal and axonal marker 
associated with neuronal viability), myo-inositol (a cerebral osmolyte and an astrocytic 
marker), glutamate and glutamine (the first is a major excitatory neurotransmitter and the 
second can restore it), creatine (which plays a crucial role in ATP biosynthesis in astrocytes), 
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choline (its increased concentration theoretically means an alteration of myelin) and gamma-
amino butyric acid (a main inhibitory neurotransmitter) (Martin, 2007). But MRS can also 
record intrinsic containing metabolites containing other atoms, as phosphorus, sodium, 
potassium, carbon, nitrogen and fluorine (this last atom often being a constituent of many 
drugs). Among the functional imaging techniques, positron emission tomography (PET) is a 
three-dimensional diagnostic imaging technology used in nuclear medicine that measures 
physiological function by looking at various functions of the body. It is a non-invasive 
diagnostic imaging tool enabling to follow some chemical neurotransmitters like dopamine 
in Parkinson’s disease. Whatever the technique used to cover a specific neurological 
question, most of the time, it often requires laboratory animal and more particularly animal 
models of given human diseases. 
2.4 Laboratory animals model contribution 
The use of animal models in clinical research is crucial. As models, they usually display the 
same features and clinical signs as those observed in humans. So, they enable to establish some 
comparisons and extrapolations with the human physiology, to give access putative metabolic 
mechanisms involved in the progression of the disease and, hence, to identify biomarkers. A 
wide range of animal models has been used according to their origin. Animal models can be 
spontaneous, namely “mutant”. Therefore, identification and characterization of novel 
laboratory animal lines carrying an interesting mutation combined with genotype-driven 
approaches are useful approaches to investigate some specific mechanistically-related 
molecules, to give new information about the function of the mammalian nervous system 
(Banks et al., 2011) or to study how genetic, environmental, toxicological or dietary factors can 
explain aetiology of a given disease. Animal models can also be created, using surgery, 
pharmacology or genetic interventions. These models are used to identify aetiological markers 
of disease or drug target and to test some new therapeutic drugs. The first cases have 
traditionally been induced by neurotoxins, acting selectively on neurons affected by human 
diseases. They are particularly useful for the study of the pathogenetic mechanism or to test 
new therapies for human neurological disorders (psychiatric or motor disorders) like 
obsessive-compulsive disorder or Parkinson’s disease (Nowak et al., 2011). In parallel, the 
knockout technique, in which a gene is made inoperative leading to animals deficient in one 
specific gene, enables to evaluate the effects of the depletion of one protein in all the series of 
biological reactions within an organism and the putative followed consequences (Berman et 
al., 2011). More recently, the use of transgenic animals, constructed by inserting a human gene 
downstream into promoter, followed by microinjection in animal, ensures to indicate whether 
an over- or under-expression of a gene in one or several tissues should be susceptible to 
promote the pathogenesis and the development of a disease (Liu et al., 2011). The common 
point of all these animal models is the necessity of having some preliminary knowledge 
concerning a disease or the deleterious effect of a given xenobiotic. However, this information 
is not always available. Therefore, researchers have apace become aware of the necessity to 
access a wider range of knowledge in a living system and not only a specific molecular entity. 
3. “Omics” approaches and their interest in clinical research 
3.1 “Omics” approaches presentation 
Similarly to imaging techniques, omics-based approaches appeared to be used according to 
the biological pool they consider (genes, proteins, lipids, metabolites) and the nature of 
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target they have to reach (gene, enzymatic mechanism, biomarker). The full range of 
metabolites synthesized by a given biological system corresponds to its metabolome. In the 
same way, the full range of genes is contained in the term genome, the mRNA and the 
proteins ones, respectively, in the terms transcriptome and proteome (Figure 2). All these 
systems can be defined according to the level of biological organization, i.e. organism, organ, 
tissue, and cell. Related to these biological levels, omics-based approaches, mainly 
genomics, transcriptomics, proteomics (Colucci-D'Amato et al., 2011), lipidomics (Li et al., 
2007), and metabolomics are terms standing for various global molecular-oriented 
approaches to better understand the underlying mechanisms, as the physiological 
regulations and the networks involved on all levels of gene products (mRNA, proteins, 
metabolites) in their respective systems and, if possible, between different sub-networks. 
Indeed, the observable property of organisms, i.e. their phenotype, is issued from genotype 
submitted to the concomitantly interactive action of the environment. Most of the time, the 
association between some of these approaches can be beneficial, enabling to understand the 
temporal progression of a pathophysiological state or the functioning of metabolic networks 
(Fiehn, 2001). Interest of these methods is to apply a controlled disruption to a biological 










































Fig. 2. “Omics” approaches and their different levels of biological living systems investigation 
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specific conditions (most of the time, the investigation is focused on an animal model), and 
to consider the subclinical consequences of such a disruptive perturbation. Therefore, 
“omics” approaches are widely used in biomedical research to make easier the 
understanding of disease mechanisms and to give access target tissues, to make easier the 
identification of biomarkers useful for therapeutic and diagnostic development and to 
predict clinical responses to treatments. The large amount of acquired data is as much an 
advantage as a hindrance. Indeed, the challenging subtlety is that all this information needs 
to be explored without any a priori hypothesis but by extracting only the interesting data. 
This fact partially explains why the real capacity of “omics” technologies stays in some 
instances rather limited because of the necessary requirement of some specific 
bioinformatics tools to efficiently mine multidimensional data but also the requirement of 
some specific analytical database to identify the candidate biomarkers at the gene, mRNA, 
enzyme, protein, or metabolite level. Moreover, transcriptomic studies require high-cost 
technologies and so, are less used than proteomic ones, which are based on two-dimensional 
gel-electrophoresis, which is cheaper and can be more easily used in many laboratories. 
However, analytical techniques related to the detection of large arrays of metabolites seem 
more robust, the resulting information being often easier to interpret because of the lower 
number of molecular entities, even though a rigorous identification of new metabolites still 
remains particularly fussy. According to the aim of studies and considering an increasing 
level of complexity of the analytical strategy used, investigation of metabolites may require 
either a metabolic profiling approach, which is focused on a small number of known 
metabolites (targeted metabolic profiling), or metabolomics including investigation of 
several classes of compounds (open metabolic profiling) or functional genomics, also called 
metabolic fingerprinting or metabonomics. This latter one is based on classification of 
samples according to their biological relevance to the studied disruption event and on 
identification of the fully informative markers detected at the statistical and functional sides 
and measured within the analyzed biological matrices. 
Therefore, among these omics-based approaches, metabonomics stands for one of the most 
used holistic methods. Its emergence and its development mainly come from pioneering 
works of Pr J. Nicholson from the Imperial College of London. Because metabonomics 
enables to identify and quantify simultaneously low molecular weight compounds 
(metabolites) using spectroscopic methods such as nuclear magnetic resonance (NMR) or 
mass spectroscopy (MS), it gives access to a molecular level and may define the quantitative 
measurement of multiparametric metabolic responses of living system to pathophysiological 
stimuli. This can bring to the determination of some comprehensive metabolic signatures of 
biological matrices (Nicholson et al., 1999; Robertson, 2005). Metabonomics approach can be 
divided into successive steps. After the crucial step concerning the development of the 
experimental design, the choice of the animal model, the choice of the instrumentation used 
to quantitatively generate the metabolic information, the choice of samples of interest to be 
collected during the animal or the human experiment (biofluids such as plasma, urine, 
cerebral spinal fluid, saliva or faeces, tissues or organs), these biological samples are treated 
using appropriate analytical techniques. These latter ones enable to establish a metabolic 
fingerprint through the spectrum recording for every sample. All these fingerprints are 
summed up into datasets, in which metabolic information is subdivided and identified 
through coding variables. Each of them stands for either an integration bucket in NMR 
spectra corresponding to a defined chemical shift, or a relative or an absolute intensity of the 
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 ionic current measured at a specific mass to charge ratio in MS. Datasets are then treated 
using sophisticated statistical tools, i.e. multivariate or multidimensional statistical analysis 
tools, to access the most suitable model able to discriminate the different groups of samples 
according to the studied factors and to reveal main variables explaining this segregation. 
These variables can be considered at this step as many putative biomarkers, which need to 
be fully characterized by convenient structural identification methods. Finally, a detailed 
map of regulation and interaction between identified metabolites, their disruptions and the 
putative explanation of the pathophysiological state according to all involved factors may be 
suggested. Among analytical techniques mainly used in metabolomics, MS spectroscopy 
coupled to liquid (LC-MS) or gas chromatography (GC-MS) and NMR spectroscopy are the 
most appropriate ones concerning analysis of biofluids or liquid samples, whereas high 
resolution magic angle spinning (HR-MAS) NMR and MRS are adapted to solid samples 
like tissue or to achieve in vivo studies, respectively. 
3.2 An integrated and functional approach 
As previously mentioned above, the major constraint the “omics” approaches have to 
answer to, is to give access to a global pool of information belonging to the living system 
without focusing on a specific molecular entity. Indeed, one of the main assets of these 
approaches is the property of data integration necessary to render it as functionally 
understandable as possible. These features can be revealed through three complementary 
characteristics, namely i) the global nature of living systems underlined by homeostasis, ii) 
the multifactorial nature of diseases with both intrinsic and extrinsic factors, and iii) the 
ability to access multiple biological levels in living systems, and then to compile them to 
reveal one of the most realistic progressions of a disruption within a complex organism. 
Let’s go into details of these three points. i) Contrary to classical biochemical approaches, 
which are set out to study only a single or few metabolites or metabolic reactions at the 
same time, metabolomics provides quantitative data on a wide range of known and 
unknown metabolites. It enables to visualize an overall pattern comprehensively linked to a 
set of interactions between metabolites or metabolic pathways and, hence, to an intrinsic 
homeostasis defined in these specific conditions (Kaddurah-Daouk et al., 2008). Indeed, 
whatever the stress applied on living systems, some allostatic changes, defined as an 
adaptive process, lead to short-term corrective changes of the different relevant regulatory 
systems to maintain a metabolic homeostasis. Concept of homeostasis is fundamental in 
biology and in clinical medicine to understand pathophysiological processes. The current 
clinical medicine tends now to come back to a more global view and, at the same time, on a 
more individualized approach of every patient because each of them differently answers to 
the environment according to their own homeostatic specificity. Clinical and subclinical 
signs give personalized information for every subject and, hence, physiological “means” 
used to adapt for everybody the set of parameters of homeostatic control in response to a 
disruptive stimulus and so to avoid falling down in a pathological state. The understanding 
of overall adaptation requires a good knowledge of metabolic pathways and related 
biochemical networks involved in the efficient control of homeostasis. For example, the 
knowledge of the glucose metabolism and the different ways by which homeostatic control 
of the circulating glucose concentration is achieved is crucial in the investigation of the Type 
2 diabetes (Fiehn et al., 2010). ii) From global approaches can emerge a more accurate 
understanding of a given disease considering it is not only a single functional entity which is 
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concerned, that is not only the consequence of a single causative explanation with a single 
mechanism involved in a single cell type in a given condition. Indeed, most of the 
pathophysiological disorders are not unique functional events but are resulting from 
complex interactions. These latter ones involve different concomitant actions in different 
biological compartments leading to different disruptions, which can be categorized 
according to the environmental conditions encountered and the inherent variability of 
subjects. Becoming aware of the importance of the environment and, more particularly, of 
the multifactorial nature of most of the disruptive events displayed by a living system is 
among the first pillars of the concept of global approach used in biological research in 
clinical medicine or in toxicology. iii) Finally, as a microscope could do it, omics-based 
approaches enable to focus on a specific level of a living system depending on the available 
analytical techniques used to generate data, but also to statistically integrate data coming 
from complementary fingerprinting techniques by using canonical analyses. 
3.3 A metabolomic-based approach to reveal subclinical metabolic disruptions:  
A powerful tool in investigation of biomarkers 
Besides the ability to define and to understand the aetiology of a disease, the discovery of 
novel biomarkers stands for a fundamental step to characterize and to manage it, especially 
to spot the homeostatic break down before appearance of the first clinical signs. Biomarkers, 
which are relevant indicators of disrupted biological processes in a given pathophysiological 
context, have to disclose features of disease (Moore et al., 2007; Nicholson and Lindon, 
2008). The metabonomic approach is particularly interesting to explore subclinical 
disruptions of a living system before the outset of manifest clinical signs, and to identify 
biomarkers of disease risk and, if possible, to initiate prevention like in cancer (Roberts et al., 
2011), diabetes (Wang et al., 2011), or nervous system illnesses (Kaddurah-Daouk and 
Krishnan, 2009; Nicholson and Lindon, 2008; Quinones and Kaddurah-Daouk, 2009). The 
identification of the metabolites requires the use of up-to-date structural databases of 
metabolites and metabolic pathway resources (Kouskoumvekaki and Panagiotou, 2011). As 
it has been previously mentioned, the use of complementary approaches stands for a  
wise way search of biomarkers displayed at different levels, namely biochemical, 
neuroanatomical, metabolic, genetic and neuropsychological ones, as it can be reported in 
the case of Alzheimer’s disease investigation (Wattamwar and Mathuranath, 2010). 
3.4 Examples of “omics” approaches in neurological investigation area 
Use of metabolomics in neurological studies has been reported in many reviews (Choi et al., 
2003; Rudkin and Arnold, 1999). It has been applied to a variety of biological samples for a 
better understanding of pathogenesis. This approach, because of its integrated and 
functional nature, stands for a powerful tool to study normal or pathological living systems, 
especially in central nervous system disorders through the use of specific animal models 
(Pears et al., 2005). Thus, it allows the identification of biomarkers of such diseases, but also 
of illness progression or response to therapy. In the drug discovery process, metabolomics 
brings some biochemical information about drug candidates, their mechanism of action and 
their therapeutic potential. In the field of neurosciences, the use of metabolomic approach 
can generate some questionings. Contrary to other organs in mammals, brain is isolated 
from the rest of organism by the blood-brain barrier, with consequences on the passage of 
some metabolites. Therefore, a metabolic fingerprint of brain predicted from a blood or 
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urine metabolomic analysis is not prone to reflect the real state of the subject, contrary to 
data coming from other organs like liver and kidney. Nevertheless, some first encouraging 
studies on neurological disorders performed using metabolomics have confirmed the 
interest of application of this approach in the field of neuroscience (Griffin and Salek, 2007). 
Analysis of blood or urine gives access to putative cerebral disruptions and can help to 
successfully reveal some biomarkers, as in the case of the manganese neurotoxicity, which is 
a significant public health concern (Dorman et al., 2008). So, because it reflects the presence 
of both extrinsic and intrinsic disruptive factors, metabonomics can define accurate 
biomarkers in neurology. Moreover, some specific metabolic pathways or some biological 
disruptions can be particularly interesting to study, because of their central or ubiquitous 
role in many pathological states. One example is the oxidative stress, leading to neuronal 
death, a mechanism that is found in early stages but also in secondary manifestations of 
many neurodegenerative states like Alzheimer’s, Parkinson’s and Huntington’s diseases, 
amyotrophic lateral sclerosis, and neuroinflammatory disorders (Sayre et al., 2008). Because 
of the pivotal role of a metabolite in many biological functions, a 
better understanding of some metabolic pathways like the biosynthesis of the amino acid  
L-serine can be interesting to investigate (Tabatabaie et al., 2010). Metabolic profiles 
acquired on human or animal biofluids like urine, cerebrospinal fluid (Lutz et al., 2007b), 
plasma, serum or tissue extracts, using either NMR or MS techniques, can give some 
precious information concerning neurological disorders (Sinclair et al., 2009). For example, 
ultra performance liquid chromatography/mass spectroscopy (UPLC/MS) metabolic 
profiles from serum collected on cerebral infarction patients have been analyzed using a 
metabonomic approach (Jiang et al., 2011). Quantitative analysis of human cerebrospinal 
fluid using NMR spectroscopy has been performed in multiple sclerosis (Lutz et al., 2007a), 
to identify biomarkers in the early stages of the amyotrophic lateral sclerosis (Blasco et al., 
2010). Plasmatic metabolic disruptions between healthy and old persons with Alzheimer’s 
disease were investigated using UPLC/MS-based metabonomic approach (Li et al., 2010). 
CRND8 transgenic mouse, model of this disease, enabled to analyze brain extracts using  
1H NMR spectroscopy (Salek et al., 2010). The interest of brain extracts coming from an 
animal model has been also illustrated to investigate epilepsy, for which the 
pharmacologically-induced animal model was obtained using pentylenetetrazole, a drug 
that induces seizures (Carmody and Brennan, 2010). Plasma from an experimental animal 
model of the spinal cord injury (Blasco et al., 2010) has been analyzed by 1H NMR to get 
fingerprint profiles of this pathology (Jiang et al., 2010). Other cerebral alterations like brain 
tumors (Tate et al., 1996; Tate et al., 1998), schizophrenia and meningitis (Holmes et al., 2006; 
Lutz et al., 2007a) have also been investigated. 
Beyond the use of a unique “omics” approach, it seems that it is all the more interesting and 
powerful to call for several complementary approaches and to tend to integrate so-
generated data to yield a more comprehensive understanding of many diseases. In this way, 
Caudle et al. have used “omics” to characterize and identify some biomarkers of Parkinson’s 
disease (Caudle et al., 2010). As an example, the following part illustrates the power of such 
a use, in a rodent model, of a neuro-intoxication caused in the horse by a plant, Hypochoeris 
radicata (L.). Indeed, because of the lack of knowledge about a neurological disease 
described only in the horse, we have tempted to use a laboratory animal model of this 
intoxication by applying metabonomics combined to imaging or behavioural experiments to 
reveal, in brain, candidate biomarkers of this pathology. 
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4. Example of a metabonomic approach of a neurological horse disease, the 
Australian stringhalt or how to address a toxicological issue on a seemingly 
non-target species without referring to a known toxic molecule  
4.1 Problem for studying such an animal disease 
Australian stringhalt is the name of a horse disease described since the middle of the 19th 
century in Australia (Robertson-Smith et al., 1985). It is defined as a syndrome characterized 
by an abnormal gait and an involuntary hyperflexion of both hind limbs during movement 





Fig. 3. Horses displaying clinical signs of Australian stringhalt (grade IV on the left, grade V 
on the right) (from (Collignon, 2007)) 
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Since this time, several other outbreaks had been reported in many countries such as New 
Zealand (Cahill et al., 1985; Cahill et al., 1986; Cahill and Goulden, 1992), Chile (Araya et al., 
1998), United States (Gay et al., 1993; Huntington et al., 1989; Robertson-Smith et al., 1985; 
Slocombe et al., 1992), Italy (Torre, 2005), Brasil (Araujo), more recently in France (Domange 
et al., 2010; Gouy et al., 2005) and were suspected in Japan (Takahashi et al., 2002). 
According to most of the authors, a plant of the Asteraceae family (formerly Compositeae 
family), Hypochoeris radicata L. also named cat’s ear, flatweed or capeweed was suspected to 
be responsible for this disease (Araujo et al., 2008; Gardner et al., 2005; Gay et al., 1993; Gouy 
et al., 2005). This rosette-forming herb with a yellow terminal flower has a deep taproot, 
giving it resistance to drought. This explains a growth achieved preferentially on poor-
quality pastures after a prolonged dry period, mainly in late summer and early autumn. 
Such climatic conditions, associated with the aggressiveness and the dominance of 
Hypochoeris radicata L. on other species, enable it to colonize pastures and to become the 
major plant available as herbivore feeding. These favouring factors, in aggravation for many 
years because of the global change in climatic conditions, appeared particularly marked in 
2003 in France, after a blistering and dry summer, leading to an epizooty with a few tens of 
recorded intoxicated horses (Domange et al., 2010; Gouy et al., 2005). These latter’s showed a 
wide range of symptoms but mainly dominated by several severity degrees from grade I to 
grade V, (Huntington et al., 1989) with an involuntary exaggerated hyperflexion of hind 
limbs and a delayed extension of hocks during forward movement. A marked atrophy of the 
hind limbs musculature, especially in the distal muscles, is often associated with this gait in 
the most affected animals. Most of the time, this amyotrophy is related to neurological 
lesions of the hind limbs with a proximal-to-distal gradient in the intensity, i.e. a loss of 
fibres, a decrease of the number of large myelinated nerve fibres, in agreement with the 
supposed pathogenesis described as a distal axonopathy (Cahill et al., 1986; Domange et al., 
2010). However, in spite of these rare epidemiological and pathological data, the link 
between this horse disease and the toxicity of Hypochoeris radicata (HR) has been poorly 
investigated in spite of a recent study, which tended to reproduce the disease on animals 
after a 50-day HR treatment (9.8 kg HR/animal/day) (Araujo et al., 2008). The lack of 
investigation of such a disease is further partially explained by the critical approach of the 
nervous system, especially the peripheral nervous system and by the only target species. 
Besides, we need to consider ethical and financial issues. Moreover, as Araujo and 
colleagues underlined, the plant material is susceptible to differ in toxicity depending on 
several factors, one being the geographical location (Araujo et al., 2008).  
4.2 Concept of orthology and interest in metabonomics 
Most of the time, investigating a disease often requires a convenient laboratory animal 
model enabling to reproduce clinical symptoms, to access pharmacological data, to reveal 
some biomarkers of the disease and, in the best cases, to suggest some therapeutic 
treatments. Because of the nervous nature of Australian stringhalt, the fact that this illness 
was only described in target species, and the difficulties to link the supposed plant (more 
particularly if a specific secondary metabolite present in the plant would be involved) to the 
pathogenesis, the assessment of such an induced intoxication using a “classical” 
neurological approach seemed not efficient enough to reveal valuable biomarkers. Data 
obtained until recently remained too scarce. The “omics” approach, more particularly 
metabonomics, appears to be the most suitable mean to obtain some pertinent information 
about the target organs and candidate metabolic biomarkers by using an a priori 
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“metabolically competent” animal model. The orthologous hypothesis considered in the 
case of an induction of a metabolic disruption in a rodent animal model of another animal 
species, here horse species, is crucial in characterizing a set of candidate metabolic 
biomarkers. Even though clinical signs may strikingly differ between the two species, some 
metabolic similarities may exist between their metabolic networks, particularly in their 
ability to be similarly disrupted by one or few toxicants. Among these latter’s, plant 
secondary metabolites, for which nothing is known at the chemical and pharmacological 
sides, can be studied.  
4.3 Use of complementary approaches: 1H NMR-based metabonomics, MRI and 
behavioural tests 
4.3.1 Metabolic fingerprints on biofluids and tissue extracts 
Using the orthologous metabolic disruption assumption existing between two species, horse 
and mouse in the present case, metabonomics was used to investigate at the metabolic side 
this orphan neurological disease, Australian stringhalt. The purpose was to combine it with 
MRI as published elsewhere (Griffith et al., 2007) and with behavioural tests to improve the 
functional understanding of the metabolic data. Based on the orthologous hypothesis 
previously mentioned, the mouse was chosen as a “metabolically competent” laboratory 
animal model of horse intoxicated by HR, even though this rodent model of exposure to HR 
does not display any observable clinical sign. In a first time, metabonomic studies using 
male and female C57BL/6J mice fed for 21 days a diet containing 3 or 9% HR had been 
performed (Domange et al., 2008). 1H NMR spectroscopy analyses have been done on 
weekly collected urine samples but also on tissue extracts prepared from liver and brain 
tissues collected at 0, 8, 15 and 21 days of treatment, after sacrifice of a subpopulation of the 
animals included in the experimental design. Urine and liver analyses were performed to 
detect the putative systemic disruption after the HR ingestion, and the brain analysis to 
access the nervous system disruption. All 1H NMR spectra were acquired at 300 K on a 
Bruker DRX-600 Avance NMR spectrometer operating at 600.13 MHz for 1H resonance 
frequency, using a cryoprobe and the 1D “Improved Watergate” sequence for suppression 
of water resonance. Multidimensional statistical analyses of fingerprint data were achieved 
on log-transformed variables. After removing redundant variables, linear discriminant 
analyses and partial least-squares regression-based discriminant analyses (PLS-DA) were 
performed on NMR data to maximize the groups’ separation on a factorial map. Projection 
of these groups on every factorial axis enables to associate canonical 1H NMR variables to 
the axis construction revealing thus the respective influence of the different factors of 
interest (gender, intoxication duration, toxicant dose). Therefore, the main part of the 
metabolic information related to urine 1H NMR data and enabling the discrimination 
between the different groups of animals can be summed up in a factorial map (Figure 4). On 
this map, appears the temporal evolution between day 0 and day 21 of the metabolism of 
animals. This latter depends significantly on the gender of mice, through the 1st axis (this 
factor contains the main part of the variance explained by the statistical model used) and on 
the diet factor, through the second axis, covering from the bottom part of the factorial map 
diets without HR (named “control”) to the middle part, diets with 3% HR (named “3%HR”), 
then to the top part, diets with 9% HR (named “9%HR”). By searching the first variables 
involved in the second axis construction, we reached the main metabolites, the 
concentration of which was influenced by a HR-induced metabolic disruption (Domange et 
al., 2008). 
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Fig. 4. LDA performed on 150 metabolic variables selected from fingerprints obtained by 1H 
NMR performed at 600.13 MHz on 332 urinary samples (from Domange et al., 2008). The 
dummy variable selected is the « group » factor. A 61.5% amount of the total metabolic 
information is projected on the factorial plan LD1 x LD2. Arrows stand for metabolic 
trajectories throughout the study followed by every group fed either a control or a 3 or 9% 
HR diet. Barycenters give the dates of urine collection and correspond to the duration of HR 
intoxication (d8, day 8; d15, day 15; d21, day 21) 
 
 
Fig. 5. LDA performed on 20 variables filtered from 600.13 MHz 1H NMR data of brain 
aqueous extracts from male and female mice according to groups and in agreement with the 
two first components (from Domange, 2008). Barycenters give the date of brain collection 
and correspond to the duration of HR intoxication (d8, day 8; d15, day 15; d21, day 21) 
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In a same way, the main part of metabolic information contained in 1H NMR data 
characterizing liver and brain hydrosoluble extracts and enabling the discrimination 
between the different groups of animals during the experiment could be summed up into a 
more complex factorial map (Figure 5). Firstly, is displayed the temporal evolution of the 
brain metabolism of mice orally exposed or not to HR, which holds almost all the part of the 
variance explained by the statistical model with, respectively from the right to the left side, a 
projection of the cerebral metabolisms of control animals, then the 3%HR-treated mice, and 
finally, the 9%HR-treated ones (Domange, 2008). The factor “time” is clearly revealed 
through every HR treatment with, respectively, from the right to the left side, an emphasis 
of the disrupted metabolism in a given direction all along the experiment duration. Given 
the fact that the two matrices of 1H NMR fingerprinting data obtained on hydrosoluble 
brain and liver extracts were issued from the same individuals, a global correlation using a 
canonical analysis (PLS2 here) have been performed between them. A significant correlation 
between the two first PLS2 components has been revealed (Figure 6), in which, the gender 
factor is orthogonally projected to the diet one. Concerning the projection of variables 
involved in the variance calculation, i.e. the information explaining this construction, on the 
same plot, we can show that liver and brain 1H NMR fingerprint data display close  
 
 
Fig. 6. Resulting biplot performed on the two first PLS2 components calculated between the 
hydrosoluble liver and brain extracts (from (Domange et al., 2008). Only the projection of 
the variables with contribution is above 0.5 is displayed (in grey for brain variables, in pink 
for the liver ones). Most of the variables containing the variance explained by the statistical 
model is spread according to the gender factor for the liver and according to the diet 
concerning the brain. The brain variable named B3.34 (arrow numbered 1) and the 
corresponding liver variable named L3.34 (arrow numbered 2) stand for the scyllo-inositol, 
detected at δ = 3.34 ppm. The brain variable named B3.60 (arrow numbered 3) and the 
corresponding liver variable named L3.60 (arrow numbered 4) stand for the myo-inositol 
detected at δ = 3.60 ppm 
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Fig. 7. 600.13 MHz 1H NMR spectra from aqueous extracts of brain in 9% HR-treated mouse 
and control mouse (from Domange, 2008) 
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information. Among the main variables involved in the segregation of the groups of 
animals, i.e. which are related to the HR-treatment factor, and whatever the biological 
matrix analysed, the first identified variables correspond to the chemical shifts of the scyllo-
inositol (δ = 3.35 or 3.36 ppm in urine and in liver extract fingerprints, δ = 3.34 ppm in 
cerebral and liver fingerprints), which are positively correlated to HR-treatment, when the 
myo-inositol ones (δ = 3.60 ppm) are negatively correlated to HR-treatment (Figures 7 and 8). 
Moreover, the comparison between 1H-NMR metabolic fingerprints in control and HR-fed 
laboratory animals revealed a dose-dependent increase of the ratio scyllo-inositol/myo-
inositol in urine, plasma, and hydrosoluble extracts of liver and brain of the HR-treated 
animals, enabling us to reveal some putative candidate metabolic biomarker(s) even though 
no aetiological factor was characterized, and no requirement of the target species was 
performed in this toxicological exploration. 
 
 
Fig. 8. Loading plot from O-PLS models performed from the aqueous extracts of brain in 9% 
HR-treated mice 
4.3.2 Magnetic resonance imaging 
To get access in situ to some potent cerebral metabolic changes thanks to a second 
spectroscopic technique, 1H NMR localized spectroscopy, six male mice given a 9% HR diet 
and six control mice were used for in vivo metabolite quantification. All experiments were 
performed at 9.4 T on a Bruker Avance DRX 400 microimaging system with a wide-bore 
vertical magnet and a Micro 2.5 gradient system (Bruker Ettlingen, Germany). Because a 
preliminary experiment performed on a spectroscopic volume of interest (VOI) positioned 
in the cortex of mice was inconclusive, spectra have been performed from 1H NMR data 
acquired by in vivo MRI using a VOI positioned in the thalamus of control and 9%  
HR-treated male mice (Figure 9.a). In this region, only the 9% HR-treated mice displayed a 
significant although minor signal found at δ = 3.34 ppm corresponding to scyllo-inositol 
(Figure 9.b). A one-way ANOVA performed for every other identified variables quantified 
at the same time from raw integrated spectra coming from in vivo MRI enables us to give 
significant results only for scyllo-inositol (p = 0.0013). As it could be described above, and as 
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one of the interests of metabonomic approach is to combine data generated by different 
techniques to get more powerful biomarkers, a PLS2-based canonical regression between  
the set of brain metabolites issued by in vivo MRI and the 1H NMR fingerprints of 
hydrosoluble brain extracts performed on the same animals has been obtained after 
correction of the two data sets by an OSC-PLS-driven correction procedure. The canonical 
analysis obtained by the PLS2 analysis between these two corrected data sets showed that 
the 1H NMR variable called B3.34, namely scyllo-inositol, was projected in the region where 
scores of HR-treated animals were also projected (Figure 9.c). Moreover, the relative contents 
of N-acetyl-aspartate (NAA), lactate and choline were increased (p < 10-5, p = 0.02 and  
p = 0.03, respectively) whereas the glutamine one was decreased (p = 0.04) in response to the 
9% HR treatment. MRI studies were also conducted in poisoned living mice and 
corroborated the abnormal higher presence of scyllo-inositol in the thalamus of poisoned 
animals. Even this result was unable to explain the exact pathophysiological mechanism 
involved and the outset of the illness, it confirmed that scyllo-inositol was a biomarker of 
interest in the central nervous system, particularly when it is related to some brain metabolic 
disturbances (Griffith et al., 2007; Jenkins et al., 1993; Viola et al., 2004). The increase in 
NAA, which has been previously revealed following MRI and 1H NMR spectroscopy of 
hydrosoluble brain extracts was suggested to be linked to the enhanced locomotor activity 
observed in 9% HR-treated mice. Besides, NAA has been reported in epileptic seizures cases 
(Akimitsu et al., 2000).  
This accumulation of NAA has also been shown in a rat model of the Canavan’s disease, 
suggesting that NAA increase in brain should be linked to neuroexcitation and 
neurodegeneration (Kitada et al., 2000).  
4.3.3 Behavioural testing 
The two previous exploratory studies led us to consider in more details the role of inositols 
in the development of the Australian stringhalt. The location of such metabolic disturbances, 
the current knowledge of the metabolism and the pathways involved, such as 
neurotransmission, signalling system and regulation of many cellular functions, depending 
on the balance between scyllo and myo inositol needed to be rounded out by a 
complementary functional assessment as a large extent behavioural testing of HR-treated 
animals can provide it. Indeed, the administration of inositol (myo-inositol) is used as a 
therapeutic molecule in depression (Einat et al., 1999), panic disorder, obsessive-compulsive 
disorder (Cohen et al., 1997; Levine, 1997). It partially explains an enhanced locomotion 
(Kofman et al., 1998) and may be linked to a putative anxiolytic effect (Kofman et al., 2000) 
with possible involvement of serotoninergic (5-HT2) receptors (Einat et al., 2001). Therefore, 
to investigate the functional consequences of such previous disrupted metabolic events, 
various behavioural aspects of C57BL/6J mice orally exposed to 9% HR for 3 weeks were 
performed in parallel with the 1H NMR metabolomic exploration of the brain. Several 
behavioural tests related to locomotor activity (open-field test), motor coordination 
(Locotronic® apparatus, Wespoc test), learning and memory [Y maze, (Hughes, 2004), Figure 
10.a and Morris water maze], anxiety [elevated plus maze, (Rodgers and Johnson, 1995), 
hole board (do-Rego et al., 2006; Takeda et al., 1998), Figure 10.b], and depression forced 
swimming test or test of Porsolt (Porsolt et al., 1977; Porsolt et al., 1979), social interaction 
(resident/intruder model), and addiction (place preference test) were carried out (Domange 
et al., submitted).  
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Fig. 9. a) MRI performed at 9.4 T on a Bruker Avance DRX 400 microimaging system 
positioned in the thalamus region with an in vivo parallel metabolite quantification using  
1H NMR localized spectroscopy (VOI, 12 mm3). b) Spectrum comparison between the sum 
of six 1H NMR spectra acquired on control male mice and the sum of six 1H NMR spectra 
acquired on 9%HR-treated male mice with the presence of scyllo-inositol (chemical shift 
detected at δ = 3.34 ppm). c) PLS2 between MRI quantitative data and 1H NMR data.  
A loading projection is given for metabonomic variables having a norm above 0.5 (pale blue 
circle) or above 0.75 (pale green circle). The purple and the dark-blue ellipses, respectively, 
correspond to the scores of control and 9% HR-treated mice. Among the main MRI loadings 
having a positive correlation with HR treatment are scyllo-inositol (s-Ins), N-acetyl-aspartate, 
lactate and choline. For MRI variables having a negative correlation with HR treatment are 
glutamate (Glu.2, second chemical shift) and glutamine (Gln.2, second chemical shift). 
Uninformative MRI loadings: myo-inositol (m-Ins), glutamate, first chemical shift (Glu.1), 
glutamine, first chemical shift (Gln.1), GABA, taurine and unknown 1 are projected in the 
centre of the biplot (from Domange et al., 2008) 
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                          (a)                                                           (b)                                                 (c) 
Fig. 10. Examples of behavioural tests used in mice: a) Y-maze or Y-maze spontaneous 
alternation that estimates the immediate working memory performance. b) Hole board test 
that evaluates the exploratory rate and the anxiety level. c) Forced swimming test defined to 
visualize a depression state (from Domange et al., submitted) 
Although the lack of motor coordination impairment is commonly observed in the sick 
horses, 9% HR-treated mice displayed a motor hyperactivity, which is reflected by the 
decrease of immobility time in the forced swimming test, and the increased numbers of 
head dipping in the hole board test, of arms visited in Y-maze and of the number of entries 
in the upper quarter of the maze in the Morris water maze (Domange et al., submitted). This 
increased activity of treated mice, which is clearly observable at the end of tests, could be 
linked to a decrease in the resignation state or an enhanced motivation. Moreover, the 9% 
HR-contaminated mice seem to be addicted to the plant as indicated by results obtained in 
the place preference test. A regularized canonical analyses performed using mixOmics, an R 
package (Le Cao et al., 2009) to establish a canonical link between the two multidimensional 
data sets, i.e. the one containing the 1H NMR fingerprints of hydrosoluble brain extracts and 
the one corresponding to the behavioural data set, which comprises nearly 100 variables, 
has revealed a clear relationship between some behavioural impairment variables (the 
motor hyperactivity and the addiction for the plant) and the main metabolic disruptions, i.e. 
the increase in scyllo-inositol in the brain of HR-treated mice and the relative decrease in 
myo-inositol. These results underlie the interest of such a dual and combined approach to 
characterize the functional end-points of a pathophysiological model of the horse Australian 
stringhalt in a seemingly metabolically orthologous murine species. 
5. Conclusion 
In this chapter, we underlined the interest of “omics” approaches and their recent 
introduction in the field of neuro-toxicological research. Indeed, metabonomics can 
especially be considered as a potentially powerful mean to explore the subclinical 
disruptions of an organism before the outset of clinical signs, and would particularly be 
useful in discovery markers of disease risk. This approach would help to prevent some risks 
in spite of the difficulty to detect some minor metabolites or molecules in tiny doses or 
mixtures, with the ability to access and explore some isolated and intricate tissues (like 
brain) via the general metabolism (urine, plasma) and to link statistically these subclinical 
metabolic changes with complementary data coming from other phenotyping approaches 
and across multiple physiological levels. Besides, these combined techniques have been 
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applied in some toxico-environmental assessments possibly aetiologically linked to some 
neuro-physiological diseases. Thus, coupling metabolomic and behavioural studies may 
help to functionally describe neurotoxicity resulting from ingestion of milk of lactating  
goats fed a hay contaminated with various persistent organic pollutants (POPs) like  
Polycyclic Aromatic Hydrocarbons (PAHs), PolyChloroDibenzo-p-Dioxins (PCDDs), 
PolyChloroDibenzoFurans (PCDFs) and PolyChloroBiphenyls (PCBs) (Schroeder et al., in 
preparation). Nevertheless, these “omics” technologies required new specific bioinformatics 
tools to mine multifactorial data and, in the case of metabolomics, some well-documented 
analytical databases to structurally characterize metabolites revealed as candidate 
biomarkers. Therefore, further progress needs to be obtained to improve at the statistical 
side these integration strategies and to reduce some still existing drawbacks. Nonetheless, 
such techniques have also the outstanding capacity to give some interpretation of the results 
in a larger biological perspective, given that this holistic approach stands for an emerging 
level of knowledge in clinical medical research. 
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